دراسة الفعالية الخافضة لسكر الدم لمضادات الإلتهاب اللاستيرويدية الانتقائية (سيليكوكسيب، روفيكوكسيب، فالديكوكسيب)‎

Abstract EN

Selective Cyclo Oxygenase Enzym (COX-2) inhibitors, such as Celecoxib, Rofecoxib, and Valdecoxib, are recently accused with synergic effect for anti-hyperglycemic agents (Sulfonylurea group), such as Glibenclamide (GBM) which is used in the treatment of Type II Diabetes Mellitus (TII DM).

In this research, we present in-silico dependant theory that may explain that synergic effect, by using rigid docking tool, considering the chemical fact that COX-2 inhibitors are also sulfonamide derivatives just like sulfonylurea drugs.

As a result, the three compounds had bound to Kir6.2\SUR1 receptor in the same binding site of GBM.

These findings led us to suggest that COX-2 inhibitors bind to Kir6.1\SUR1 receptor, which explains this activity.

This emphasizes the medical recommendations to avoid using these two medical groups at the same time for TII DM, because of the adverse effect that may be presented as a sudden hypoglycemia.